Skip to main content
Walvax Biotechnology Co.,Ltd. logo

Walvax Biotechnology Co.,Ltd. — Investor Relations & Filings

Ticker · 300142 ISIN · CNE100000WN2 LEI · 300300H82R2DIQXA8N24 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,790 across all filing types
Latest filing 2023-03-29 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300142

About Walvax Biotechnology Co.,Ltd.

https://www.walvax.com

Walvax Biotechnology Co.,Ltd. is a biopharmaceutical enterprise specializing in the research, development, production, and distribution of vaccines and other biological products. The company focuses on modern biotechnology to address public health challenges through a diverse portfolio of preventive vaccines. Key products include the 13-valent pneumococcal polysaccharide conjugate vaccine (PCV13), the bivalent human papillomavirus (HPV) vaccine, and various combination vaccines for meningitis and Haemophilus influenzae type b (Hib). Walvax operates advanced R&D platforms and manufacturing facilities that comply with international quality standards. The company is actively involved in the development of next-generation vaccine technologies, including mRNA and recombinant protein platforms, aiming to provide affordable and high-quality immunization solutions for global markets.

Recent filings

Filing Released Lang Actions
2022年度独立董事述职报告（赵健梅）
Board/Management Information Classification · 95% confidence The document is titled as an independent director's annual report for the year 2022 from Yunnan Watson Biotechnology Co., Ltd. It details the independent director's activities, attendance at board meetings, opinions on various company matters, committee work, investigations, investor protection efforts, and training during the year. The content is a detailed narrative of the director's duties and opinions rather than a financial report or announcement. It is not a full annual report (10-K), audit report, or earnings release. It is also not a regulatory filing or announcement of a report publication. The document fits best as Board/Management Information (MANG) because it relates to the independent director's report on their management and governance role and activities during the year.
2023-03-29 Chinese
2022年度独立董事述职报告（曾令冰）
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2022, authored by an independent director of the company. It details the director's attendance at board meetings, opinions on various company matters, committee work, investigations, investor protection efforts, and training activities during the year. The content focuses on the director's duties and activities rather than presenting financial statements or audit results. The document length is 2657 characters, which is relatively short and more of a report or statement by a board member rather than a full annual report or audit report. This type of document fits best under Board/Management Information (MANG), as it relates to management and board-level disclosures about director activities and governance. It is not an Annual Report (10-K), Audit Report (AR), or Regulatory Filing (RNS) since it is a formal report by a board member on their duties and opinions.
2023-03-29 Chinese
关于部分募集资金投资项目结项的公告
Capital/Financing Update Classification · 95% confidence The document is an official announcement from a company regarding the completion (结项) of a specific fundraising investment project, namely the '沃森生物科技创新中心项目'. It details the use and management of raised funds, approvals from the board, supervisory board, and independent directors, and compliance with regulatory requirements. The document does not contain financial statements or comprehensive financial data but focuses on the status and management of capital raised through share issuance and its dedicated use. It is a regulatory announcement about the status of capital use and project completion rather than a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (6217 characters) and content support this classification with high confidence.
2023-03-29 Chinese
关于召开2022年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a notice for the 2022 Annual General Meeting (AGM) of Yunnan Watson Biotechnology Co., Ltd., detailing the meeting date, voting procedures, agenda items including approval of the 2022 annual report, financial reports, and other corporate governance matters. It includes instructions for shareholder registration, proxy voting, and meeting logistics. The document does not contain the actual annual report or financial statements but serves as an official announcement to shareholders about the AGM and the proposals to be voted on. The document length is 4059 characters, which is relatively short and consistent with a meeting notice rather than a full report. Therefore, this document fits the category of AGM Information (AGM-R).
2023-03-29 Chinese
关于2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2022 annual profit distribution plan by Yunnan Watson Biotechnology Co., Ltd. It details the proposed cash dividend per share, references the audited net profit, and includes opinions from the board of directors, supervisory board, and independent directors. The document states that the profit distribution plan will be submitted to the shareholders' meeting for approval. It does not contain full financial statements or comprehensive financial performance data, but rather focuses on the dividend distribution proposal and related approvals. This fits the definition of a Notice of Dividend Amount (DIV), which announces dividend amounts, payment dates, and details for shareholders. The document length is short (2178 characters), and it is not merely an announcement of a report but contains substantive dividend distribution information. Therefore, the correct classification is DIV with high confidence.
2023-03-29 Chinese
内部控制鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an "内部控制鉴证报告" (Internal Control Assurance Report) and includes detailed information about the company's internal control evaluation for the fiscal year ending December 31, 2022. It is issued by a certified public accounting firm and contains management's responsibility, auditor's responsibility, internal control limitations, and an assurance opinion on the effectiveness of internal controls related to financial reporting. The document also includes a comprehensive internal control self-evaluation report covering governance, strategy, social responsibility, corporate culture, human resources, R&D, intellectual property, production, quality management, sales, procurement, and international business. The content is focused on internal control evaluation and assurance rather than a full annual report or financial statements. This matches the definition of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles, excluding full annual reports. The document length is substantial (15,000 characters), indicating it is the report itself, not just an announcement. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-03-29 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.